CoChat

Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

An increasing number of research evidences indicate linkage between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD); the two most common diseases of aging. In addition, T2DM and AD also share some common pathophysiological features. Therefore, dual therapy that targets both the diseases can be regarded as a beneficial approach. Acetylcholinesterase (AChE) and beta-secretase (BACE) have been considered as potential therapeutic targets for AD. Accordingly, the piece of work presented here describes the binding of anti-diabetic drugs (Jardiance, Suiny and Nesina) with AChE and BACE so as to further investigate connecting bridges concerning the treatment of these two diseases. We have used "Autodock 4.2" for docking experiments. Both, hydrogen bond and hydrophobic interactions were found to be involved in the proper positioning of these diabetic drugs within the catalytic site (CAS) of AChE and BACE enzymes to permit docking. Free energy of binding (ΔG) for 'Jardiance-AChE', 'uiny-AChE' and 'Nesina-AChE' CAS interactions were found to be -9.21, -7.32 and -10.66 kcal/mol, respectively; while for 'Jardiance-BACE', 'Suiny -BACE' and 'Nesina-BACE' CAS interactions the same were determined to be -8.91, -8.58 and -10.40 kcal/mol, respectively. Hence, these diabetic drugs might act as potent dual inhibitors for the treatment of diabetes-associated neurological disorders. Consequently, the results described herein may form the basis of future dual therapy against the same.

Overview

Integrity signals

Registry

Crossref · 10.2174/1871527315666161003125752

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 13

Metadata

Authors
Shaikh, S., Rizvi, S. M., Suhail, T., Shakil, S., Abuzenadah, A., Anis, R., Naaz, D., Dallol, A., Haneef, M., Ahmad, A., & Choudhary, L.
Affiliations
King Abdulaziz University (SA)
Venue
CNS & Neurological Disorders - Drug Targets
Published
2016-10-18
Volume
15
Issue
10
Pages
1216-1221
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2527997118
Cited by
10
References
30
Citations by year
2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2019: 1
FWCI
0.27
Type
journal article
Language
en
Open access
closed
Locations
  • CNS & Neurological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
antidiabetic drugs, acetylcholinesterase, beta-secretase, dual inhibitors, Alzheimer's disease, type 2 diabetes, SGLT2 inhibitors, drug-target binding, binding free energy, dual therapy
MeSH terms
Acetylcholinesterase, Alzheimer Disease, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Humans, Hypoglycemic Agents, Models, Molecular, Computational Biology, Amyloid Precursor Protein Secretases, Hydrophobic and Hydrophilic Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. https://app.cochat.ai/papers/10.2174/1871527315666161003125752
The paper
Shaikh, S., Rizvi, S. M., Suhail, T., Shakil, S., Abuzenadah, A., Anis, R., Naaz, D., Dallol, A., Haneef, M., Ahmad, A., & Choudhary, L. (2016). Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527315666161003125752

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.